Elite Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Elite Pharmaceuticals, Inc. (ELTP) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $9.37 million for the 9-month period ending 2022-12-31, per its 10-Q filed 2023-02-14.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2023-02-14
- Elite Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-06-30 was $11.24M, a 621.74% increase year-over-year.
- Elite Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-06-30 was $1.56M, a 5.93% decline year-over-year.
- Elite Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-06-30 was $1.66M.
- Elite Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $5.34M, a 159.19% increase from fiscal 2021.
- Elite Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $2.06M.
- Elite Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$1.14M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-12-31 | $9.37M 10-Q · filed 2023-02-14 | |||
| 2022-09-30 | $10.02M 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $11.24M 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $5.34M 10-K · filed 2022-06-29 | |||
| 2021-12-31 | $4.10M 10-Q · filed 2023-02-14 | |||
| 2021-09-30 | $1.30M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $1.56M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $2.06M 10-K · filed 2022-06-29 | |||
| 2020-12-31 | $4.28M 10-Q · filed 2022-02-14 | |||
| 2020-09-30 | $3.23M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $1.66M 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | -$1.14M 10-K · filed 2021-06-14 | |||
| 2019-12-31 | -$402.11K 10-Q · filed 2021-02-16 | |||
| 2019-09-30 | -$17.91K 10-Q · filed 2020-11-16 |